Bariatrics

Austin, TX (August 6, 2015) — Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, today announced that the U.S. Food and Drug Administration (FDA) has approved the ORBERA™ Intragastric Balloon to assist adult patients suffering from obesity – with a body mass index (BMI) of 30 to […]

Austin, TX (May 18, 2015) – Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, today announced the presentation of results from the ORBERA™ Pivotal Trial at this year’s Digestive Disease Week (DDW) conference. The study showed that ORBERA™ Intragastric Balloon users lost significantly more weight than the […]

AUSTIN, TX (March 17, 2015) – Apollo Endosurgery, Inc., a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, today announced that it has appointed Stefanie Cavanaugh as Chief Financial Officer. Cavanaugh brings to Apollo Endosurgery more than 30 years of financial management experience. She will be reporting to Apollo Endosurgery’s Chief […]

AUSTIN, TX (February 27, 2015) – Apollo Endosurgery, Inc. (“Apollo”), a leader in minimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures, today announced it has closed a $50 million secured term loan provided by Athyrium Capital Management through its Athyrium Opportunities Fund II (together, “Athyrium”). The secured term loan was used to repay […]